AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Ironwood Pharma receives Buy rating from Craig-Hallum analyst Chase Knickerbocker.
ByAinvest
Wednesday, Feb 26, 2025 12:42 am ET1min read
Ironwood Pharma (IRWD) has received a Buy rating from Craig-Hallum analyst Chase Knickerbocker. The company's shares closed at $1.82 last Friday. Knickerbocker has a 5-star rating with a 13.6% average return and a 47.15% success rate. IRWD has an analyst consensus of Strong Buy with a price target of $9.25. The company reported a quarterly revenue of $91.59 million and a net profit of $31.09 million for Q3. Corporate insider activity is negative, with 43 insiders selling shares over the past quarter.
Ironwood Pharma (IRWD) has recently received a positive analyst note from Craig-Hallum, with analyst Chase Knickerbocker maintaining a Buy rating and increasing his price target from $8.00 to $9.25 [1]. Knickerbocker's optimistic outlook for IRWD comes amidst the company's strong third-quarter financial results, which showed quarterly revenue of $91.59 million and net profit of $31.09 million [4].The analyst's confidence in IRWD is not isolated. According to data from StockAnalysis.com, IRWD currently has a Strong Buy consensus rating from analysts, with a median price target of $9.25 [2]. This positive sentiment is likely driven by the company's promising pipeline, which includes its once-weekly treatment for gastrointestinal disorders, apraglutide [4].
Despite the bullish outlook, there are concerns surrounding corporate insider activity. According to data from ETFDailyNews.com, there has been negative insider trading activity at IRWD, with 43 insiders selling shares over the past quarter [3]. However, it is essential to note that insider trading activity alone should not be the sole determinant of a stock's investment merit.
As IRWD continues to navigate the regulatory and competitive landscape, investors will be closely watching the company's progress. With a strong pipeline and positive analyst sentiment, IRWD appears to be well-positioned for growth in the coming quarters.
References:
[1] https://www.etfdailynews.com/2025/01/29/analysts-set-ironwood-pharmaceuticals-inc-nasdaqirwd-price-target-at-10-00/
[2] https://stockanalysis.com/stocks/irwd/ratings/
[3] https://www.etfdailynews.com/2025/01/24/craig-hallum-issues-pessimistic-forecast-for-ironwood-pharmaceuticals-nasdaqirwd-stock-price/
[4] https://finviz.com/quote.ashx?t=IRWD
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet